Labcorp (LH) Stock Insights
LH$367.79—
Market cap$29.81BEnterprise value—Revenue (TTM)$14.59BMarket positionTop 25%
Score
40
Bearish
Value
36
Quality
47
Growth
38
Insights
- Revenue by product
- Revenue by region
| Period | Value |
|---|---|
| FY2012 | Genomic and Esoteric Testing: 2089800000.0, Ontario, Canada: 335000000.0, Routine Testing: 3246600000.0 |
| FY2013 | Covance Drug Development: 343100000.0, LabCorp Diagnostics: 5465200000.0 |
| FY2014 | Clinical diagnostics laboratory: 5682200000.0, Other Segments: 329400000.0 |
| FY2015 | Clinical diagnostics laboratory: 6199300000.0, LabCorp Diagnostics: 6199300000.0 |
| FY2016 | Clinical diagnostics laboratory: 6593900000.0, Covance Drug Development: 2844100000.0, LabCorp Diagnostics: 6593900000.0 |
| FY2017 | Covance Drug Development: 6074400000.0, LabCorp Diagnostics: 14341000000.0 |
| FY2018 | Covance Drug Development: 2189700000.0, LabCorp Diagnostics: 6664300000.0 |
| FY2019 | Covance Drug Development: 2341800000.0, LabCorp Diagnostics: 6662600000.0 |
| FY2021 | Covance Drug Development: 5845500000.0, LabCorp Diagnostics: 10363600000.0 |
| FY2022 | Covance Drug Development: 5710200000.0, LabCorp Diagnostics: 9203500000.0 |
| FY2023 | Covance Drug Development: 2774200000.0, LabCorp Diagnostics: 9415100000.0 |
| FY2024 | LabCorp Diagnostics: 10144300000.0 |
| FY2025 | LabCorp Diagnostics: 10876500000.0 |
| Period | Value |
|---|---|
| FY2012 | Ontario, Canada: 335000000.0 |
| FY2015 | CANADA: 290400000.0, SWITZERLAND: 359700000.0 |
| FY2016 | CANADA: 295800000.0, SWITZERLAND: 450500000.0 |
| FY2017 | CANADA: 327800000.0, SWITZERLAND: 484400000.0, UNITED KINGDOM: 302000000.0, UNITED STATES: 8234000000.0 |
| FY2020 | Europe: 1512200000.0, North America: 11525300000.0 |
| FY2021 | Europe: 2050800000.0, North America: 13093700000.0 |